{Reference Type}: Journal Article
{Title}: Individualization of the Dosage Regimen of Erythropoietin is Crucial in End-stage Renal Disease Patients.
{Author}: Krishnapriya MK;Karthika S;Babu A;Tom AA;
{Journal}: Saudi J Kidney Dis Transpl
{Volume}: 34
{Issue}: 5
{Year}: 2023 Sep 1
暂无{DOI}: 10.4103/1319-2442.397212
{Abstract}: The objective of this study was to understand the utilization pattern of erythropoietin in end-stage renal disease patients, along with the effect of body weight and sex on the patients' responses. In this retrospective single-center study, 120 patients were included who were on a once weekly (n = 79), twice weekly (n = 37), or thrice weekly (n = 4) regimen. The doses of erythropoiesis-stimulating agents (ESA) were collected, and the erythropoietin resistance index (ERI) was determined. The Kruskal-Wallis test was used to evaluate the dose schedules, and the once-weekly regimen produced a greater response (P = 0.001). The asymptotic significance of Pearson's Chi-square-test equating the mean ERI and body mass index (BMI) was 0.034. No statistically significant correlation was estimated between sex and mean ERI (P = 0.201). Our study demonstrated that the once-weekly regimen dominated over the others in terms of efficacy, and individuals with a higher BMI were found to respond better to the ESA therapy.